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 The pharmaceutical sector is one of the most profitable industries in 
the world, despite the very high proportion of the required research 
and development costs that determine the activity itself and the 
high risks involved in investing in them. In addition to a number of 
industry-specific characteristics, the innovation policies of each 
country might also have a significant impact on the efficiency of 
pharmaceutical companies. The primary aim of the research was to 
demonstrate this effect in the case of the Visegrád countries. The 
ROE seemed to best reflect the ownership interests and the com-
bined effect of other profitability ratios and it was confirmed by 
analysis of variance. The analysis was based on the EMIS corporate 
database; multivariate statistical methods were applied to demon-
strate the reaching of indicator trends, and from among those 
methods regression analysis was applied in particular. Based on the 
findings, it was concluded that primarily the more profitable phar-
maceutical companies were able to utilize their assets more effi-
ciently, while manufacturers in the latter category financed their 
operations with external capital to a lower extent. Although the 
indicators of the analysed companies showed a very high standard 
deviation in all four countries, the results of the regression were only 
outstanding in Slovakia, which had a very low number of cases. In 
addition, temporal tendencies have been almost the same in the 
entire region, which was also influenced by the fact that return on 
capital of the business entities within the sector decreased by 2016 
throughout the region. 
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INTRODUCTION 
As an economic and political entity, the European Union is an alliance of 28 Member States 
and an indispensable player in the global economy. The Member States of the European Union can 
be classified on the basis of various criteria, of which geographical divisions and date of their ac-
cession are the most common. EU Member States can also be classified on a political and regional 
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basis; such groups are the BENELUX countries, the Baltic States and the Visegrád Countries. From 
the point of view of the functioning of the European Union, the analysis of the operation and eco-
nomic situation of each group of countries is of paramount importance. The purpose of present 
article is to analyse the economies of four EU Member States known as the Visegrad Four, namely 
the Czech Republic, Hungary, Poland and Slovakia, including the economic situation and profitabil-
ity of active companies that operate in the pharmaceutical industry. The Visegrad Countries are the 
most dynamically developing group of countries in the EU-28. The group is likely to be further ex-
panded with some countries from the West Balkan, some of which are current EU Member States 
and some of which are expected to join the EU in the near future. Moreover, the group of V4 coun-
tries might also be extended by the EU member states of the Baltic region. This potential expansion 
process could also result in the increased role of V4 countries within the European Union (Gál, 
2018). At the time of joining the European Union, the V4 represented the seventh largest "econom-
ic block" of the EU28 (including the three Member States that joined the EU later), accounting for 
3.8% of the GDP of the EU calculated at current prices. This rate rose to 5.4 percent by 2014, con-
tinuing to hold seventh place after the Netherlands (Buzás-Német and Tóth, 2015). The economic 
situation of the V4 has been increasing slowly and to varying degrees since 1995, with GDP per 
capita at EU-28 average showing that the Czech Republic has developed the most dynamically, 
followed by Slovakia, Hungary and finally Poland. GDP per capita of Poland increased by multiple 
fractures, similar to Hungary. The development was not as dynamic as in the case of the other two 
countries. However, the V4 countries are well below the EU-28 average. (Lipták, 2018). 
 
 
1. LITERATURE REVIEW 
 
1.1 Profitability and financing trends in the pharmaceutical industry 
Calculation of profitability indicators (ROS, ROA, ROE) is of great importance in industrial and 
corporate financial analysis. Among other aspects, sector-level analysis serves to inform investors 
who are open to multiple areas, managers of industrial actors, and creditors: managers need to 
compare the financial performance of their companies with the benchmark, investors seek to 
achieve the highest return on capital, while creditors consider the probability whether companies 
will be able to repay the credits received from them (Finkler et al., 2019). The ROS indicator helps 
determine the effectiveness of activities managed by companies (Shah, 2010).  In order to maxim-
ize ROA, it is necessary to effectively manage sales prices, marketing, R&D activities, production 
and numerous other business areas (Subramanyam, 2014). Index number-based evaluation of the 
effectiveness of corporate performance, the efficiency of capital movements, and profitability of 
the utilized tools can be somewhat distorted by uncertainties related to accounting and valuation 
methods, but together they might be able to provide rational conclusions about the performance of 
a company (Helfert, 2001).  
According to the estimates of Global Database (2019), global pharmaceutical sales are ex-
pected to reach $ 1,170 billion by 2021, while the size of medical device markets are expected to 
exceed $ 400 billion by 2023, while the number of business entities involved in the pharmaceuti-
cal industry currently approaches 316 thousand. Income that is the foundation of the profitability 
of companies operating in the sector is exposed to both direct and indirect negative risks. As Dick-
son and Gagnon (2004) summarized, direct income-reducing effects include the limited medical 
aids of insurance companies, while indirect effects primarily include the reduction of pension bene-
fits, which will increase the number of people who have although retired but still do not have a 
health insurance, thus reducing the long-term scope of demand of manufacturers. Additional risks 
are identified by Dickson and Gagnon (2004): on the one hand the likelihood that, over a pro-
longed period of scientific research competing companies might gain a competitive advantage (by 
reducing return on investment and increasing their sunk cost) and on the other hand the time 
needed to approve new drugs delays product marketing and the subsequently incoming cash flow. 
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According to the calculations of Basu et al. (2008), in the case of companies that produce ge-
neric products manufacturing costs account for nearly half of their income, while in the case of 
brands, this ratio is 27%. In the case of biotechnical companies, gross margin remaining after the 
deduction of direct costs is the highest, however, within the industry these companies are mostly 
characterised by investing in R&D activities, therefore their related costs are the highest in the 
sector, as opposed to generic manufacturers, where the former costs represent only one third of 
the same values of biotech companies (Basu et al., 2008). The conclusion of the author is that 
overall, gross profitability of generic products is the lowest - compared to the sales of brands and 
biotechnology products, however the share of direct costs already showed a significant decline in 
the second half of the 2000s. 
It is generally characteristic for capital intensive and investment intensive industries to achieve 
higher return on assets at low asset turnover rates. With an average turnover rate of 1.5 in the 
analysed sector business entities are able to provide a net return on sales (ROS) of almost 11%. 
Partly due to this, the highest (more than 15%) net operating return on assets (ROA) is characteris-
tic of the pharmaceutical industry, followed by the sectors of agriculture, IT and clothing products. 
However, due to the high equity investments that are characteristic to the sector, return on equity 
is already lower in the sector than in the case of the agricultural or clothing sectors and is equiva-
lent to the approximately 13% value of retail sales (Subramanyam, 2014). 
In the study of DiMasi et al. (2016), mostly data of the top-25 companies and to lower extent 
other companies outside of it were analysed, showing that in the sector, expected returns for own-
ers and creditors declined in the 2000s on after-tax nominal value, and this trend - despite the rate 
of inflation, which was also taken into account as declining - was detectable (by 2.4 percentage 
points) in real value. It has become common for research-intensive industries that the majority of 
their investments are funded through equity rather than foreign capital (DiMasi et al., 2016), which 
may have a negative impact on their return on equity. According to Belas et al. (2017), although 
the higher bank funding of R&D companies as compared to non-R&D companies cannot be de-
tected, there is some difference among the Visegrád countries within the scope of developing 
firms: Hungarian firms typically take more bank loans for funding innovation than those based in 
Slovakia. 
Management of working capital also plays a key role in the profitability of business entities 
within the sector: Chowdhury et al. (2018) demonstrated through the analysis of East Asian phar-
maceutical companies that the length of operational cycles funded by suppliers has a significantly 
positive relation with ROA and a negative relation with ROE, while the operational cycle itself has a 
strongly negative correlation with both ROA and ROE. Thus, greater efficiency in working capital 
management is required to ensure profits. 
Profitability indicators also proved to be suitable for evaluating the performance of pharma-
ceutical business entities: analysing biotechnological companies, Anghel et al. (2018) found that 
while the relationship of their Market-to-Book Value (MTB) (which demonstrates their market value) 
with ROA and ROE is strongly negative, as opposed to previously published literature, there is a 
strong positive correlation with the efficiency rate of R&D expenditures, which makes the latter 
indicator more suitable for measuring the performance of the industrial segment that is forced to 
carry out more research activities. 
 
 
1.2 Sectoral characteristics and the role of R&D&I in profitability 
The profitability situation of pharmaceutical companies is significantly influenced by R&D ex-
penditures, even if these expenditures are capitalized by the company, since accounting of R&D for 
the given year still deteriorates its financial results (Takács, 2014, 2015). The cost of developing a 
new medicine can be planned at a relatively high risk: according to the estimations of English-
language studies published between 1980 and 2009, the highest cost was 9 times higher than the 
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lowest cost, while the extent of capitalized costs was more than $ 1.6 billion (Morgan, 2011). Di-
Masi et al. (2016) estimated the total out-of-pocket and capitalized R&D costs for a new medical 
product between approximately $ 1395 million and $ 2560 million, calculated at 2013 values. By 
the end of the 1980s, the average pre-tax cost of USA-owned pharmaceutical companies for an 
approved product reached approximately $ 114 million (DiMasi et al., 1991). However, according 
to Comanora and Scherer (2012), corporate mergers that took place in the second half of the 
2000s contributed to the observed decline of the pharmaceutical innovation rate. Douglas et al. 
(2010) also point out that the pharmaceutical industry is currently forced to face a decline in R&D 
productivity, larger barriers to the commercial success of innovative medicines and a significant 
loss of revenue originating from successful products due to generic competition. 
However, according to Cockburn (2004), the cost of medicine development will not decrease 
in the future, therefore any policy that would keep the increasing cost burden of research far from 
consumers could lead to the financial collapse of the biotechnology sector (Cockburn, 2007). Stud-
ies conducted by Berndt et al. (2015) also confirm that the returns of medicine development that 
peaked around 2000 has fallen to its lowest level in two decades due to rising development costs 
and declining demand for revenue that affected revenues, therefore maintaining medical innova-
tion in the long run might be doubtful from a financial and economic standpoint. 
However, it can be observed in the case of international pharmaceutical that their core busi-
ness and business model shifted from research and development of innovative substances to-
wards the marketing of pharmaceuticals, making it easier for them to maximize profits in devel-
oped countries (Henry and Lexchin, 2002; Lanjouw, 2002). ) and by which they are able to diversify 
their activities. The future success of non-innovator pharmaceutical companies also depends on 
the focus of their business models on exploiting the growth opportunities offered by generic prod-
ucts and emerging markets (Schuhmacher et al., 2016). To ensure a higher level of profit over the 
longer term, manufacturers also apply multiple market techniques to extend patents of their prod-
ucts, such as vigorously distributing new formulations of earlier products before putting generic 
products on the market or cooperation with generic manufacturers to keep certain products out of 
the market (Henry and Lexchin, 2002). 
Companies that contribute to the creation of major patents at a lower extent, might still be 
strategically or economically successful (Henderson and Cockburn, 1994). According to the stand-
point of Kremer (2002), through the exploitation of price discrimination profitability of business 
entities within the sector can be further increased, since it allows that the ones that value the 
product to be higher than the marginal cost of production can obtain it and thus the product 
reaches more people than it would at a single, monopolistic global market price. In addition, the 
theory of strategic intent also prevails in the pharmaceutical industry according to which aggres-
sive companies absorb all the capabilities that are required for them to stay on the market (Brown, 
2015). According to Powell (1998), business entities in innovation-oriented sectors are committed 
to becoming familiar with competitive situations. Bramhandkar (2007) also confirms the above by 
concluding that, regardless of financial performance, higher profitability can be achieved through 
market relationships and human capital and the better management of intellectual capital. 
Pharmaceutical regulatory policies can also have a significant impact on the profitability ratios 
of the sector. As described by Hutton et al. (1994), it is also clear from European examples that 
policy changes within the health sector, through more flexible pricing, might have a significant im-
pact on both the current revenues of pharmaceutical companies and future R&D decisions and 
expenditure (even if they will not become apparent for several years). Companies have also be-
come able to recognize the features of the innovation process even for developed products that 
hardly contribute to the profitability of the company (Hutton et al., 1994). In addition, patent-based 
protection of intellectual property rights is of paramount importance in order to maintain the effec-
tiveness of intensive R&D expenditures (Kovács, 2018). 
According to studies of Sherer (2001), changes in profitability measured with gross margin al-
so affect changes in R&D costs, as long as decision-makers of the sector are able to forecast 
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the changes in general industry conditions within 2 years or more. Based on the growth trends 
observed since 1962, Sherer (2001) estimates that by 2025 R&D expenditures will exceed the 
gross margin. By 2030, the process from the discovery of new formulations at an early stage to 
their commercialization will be largely outsourced, while manufacturers will seek to reduce the high 
costs of clinical trials and data collection (Sancheti et al., 2018). As stated by Sancheti et al. 
(2018), sales of generic products within global pharmaceutical sales increased by 4 percentage 
points to 10% by 2017, as the industry focused on blockbuster drugs, which are main source of 
recurring revenue of the sector (Paul et al., 2010). However, the number of marketed pharmaceu-
ticals has fallen nearly 30-fold over the past 40 years for $ 1 billion R&D costs, bringing the current 
return on such investments to only 3.2%. Higher levels in R&D spending result in the significantly 
higher market value of companies (Nord, 2011). According to the calculation of Schulze et al. 
(2014) involving the top 20 pharmaceutical companies, 25%-35% of R&D spending is required to 
return for achieving a revenue level equivalent to a 9% cost of capital within the pharmaceutical 
industry, namely it is required to increase corporate revenues through the release of new pharma-
ceuticals at an equivalent value (Schulze et al., 2014). 
The global development of research-oriented sectors would be significantly facilitated if the in-
terests of manufacturers and developers operating on different continents became relatively easy 
to harmonize, however, as Dunning and Lundan (2009) points out, in the case of the promotion of 
patented technology standards that are the framework for innovation, which is largely based on 
community investments, state interests will still be significant. The segment of the industry which 
operated in developed regions is also heterogeneous: European manufacturers are demonstrably 
more likely to launch new products than their North American competitors, while the non-
biotechnology sector performs better if the revealed patents can be linked for at least one third to 
Europe and at least the same proportion to the USA (Pammolli et al., 2011). 
 
 
1.3 Innovation policy in the Visegrád Group 
Promoting corporate innovation plays a key role in the economic policy of the Visegrád Group: 
both Hungarian and Czech tax laws provide an opportunity to deduct R&D expenditure from the tax 
base (Lengyel and Cadil, 2009). From among the Visegrád Group, Slovakia has benefited the most 
from the advantages of the EU accession, while Poland has provided the least comfortable condi-
tions for developing a competitive business environment, however this tendency has strongly im-
proved in the last decade (Molendowski and Żmuda, 2013; Wojciechowski). Owczarczuk (2013) 
also confirms that Poland has the least governmental incentives for promoting innovation, alt-
hough R&D based investments are carried out with the highest proportion in Poland among the V4 
countries. In a broader context however, Hudec and Prochádzková (2015) points out that countries 
of the Visegrád Group countries are among the worst performing countries of the EU in terms of 
innovation and competitiveness, however the Czech Republic (followed by Hungary) stand out as 
Central European countries with the best innovation performance. 
 
2. DATA AND METHODOLOGY  
The data of the companies involved in the survey were selected from the EMIS system; com-
panies having the 3254 NAICS (North American Industry Classification System) code, and operat-
ing in the "Manufacturing of Pharmaceuticals and Medicine" sector during the three years of the 
survey (2015-2017) were selected from all four countries. The data included in the analysis was 
based on the data of the annual statements of the companies, where the unit of measure was 
always indicated in million EUR. The database contains data of 37 companies from the Czech Re-
public, 63 from Hungary, 164 from Poland and 21 from Slovakia. 
In the scope of the analysis, the IBM SPSS Statistics software package was applied. First, de-
scriptive statistic elements were used. Each country was examined separately and the statistical 
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characteristics of 4 important financial variables were analysed in each country in the available 
years. The most important of these are the mean, standard deviation and α3 skewness, which fol-
lows a right skewed distribution (left leaning curve) for positive values, meaning that lower values 
are more often included in the data than high values, while in the case of negative values, the dis-
tribution is skewed to the left (right leaning curve), which means that in this case, higher values 
occur more frequently. In addition, we also examined the values of the quartiles. Correlation analy-
sis and linear regression analysis were performed to explore the relationship among the data. 
When constructing the model, some variables were logarithmized and the multivariate linear re-
gression analysis was run on these variables. In the course of the multivariate linear regression 
analysis the Backward procedure was applied, the most important elements of which are as fol-
lows: In the case of the Backward procedure, in the first step, all the specified explanatory varia-
bles are included in the model, and then the procedure continues by selecting (by means of a with 
a partial correlation value) the explanatory variable that has the smallest absolute direct effect on 
the dependent variable and then examining whether this explanatory variable has a significant 
correlation with the dependent variable. This test is performed using the partial t-test. By default, 
level of significance was set to 10% in our case. If, on the basis of the partial t-test, it is decided 
that this variable is not significant, then the explanatory variable is removed from the model and 
the previous step is performed again on the remaining explanatory variables. However, if the varia-
ble is considered to be significant, it is not removed from the model, the process stops and the 
final model is formed. The reliability of the obtained models was confirmed by means of regression 
ANOVA, and the explanatory power of the obtained models was tested by a coefficient of determi-
nation, with the R2 index. The coefficient of determination provides the percentage of the standard 
deviation of the dependent variable that can be explained by the explanatory variables included in 
the final model. This index is always between 0 and 1, and the closer it is to 1, the better the ex-
planatory power of the model. 
 
 
3. RESULTS AND DISCUSSION  
 
3.1 Comprehensive analysis of the indexes of companies operating in V4  
       countries  
Although the significance of profitability ratios for revenues and total assets is considerable in 
making financial and investment decisions and preparing sectoral analyses, it was evident from 
the results of the analysis of variance for the three variables that while no significant difference 
was found between ROS and ROA among the countries (the significance of F values in both cases 
was p> 0.05), in the case of ROE the difference was confirmed (p <0.05). For this reason, subse-
quently the different temporal development of ROE for each country was examined. 
From 2015 to 2017, the number of companies manufacturing pharmaceutical or medical 
products in the Visegrád countries increased by 8.7%. If both extreme and standing out values are 
taken into account, standard deviation gives a multiple of the mean value for each indicator and 
year, therefore the latter values are less able to represent the population of enterprises. The 
standard deviation of the sample was influenced by the fact that it also includes entities of the 
sector that have ceased their activities or are currently going out of business because they have no 
sales revenue and, according to the data recorded in the database, they have no accounted assets 
or profit. Although companies in the examined region reported overall revenue growth by 2016, 
which was also reflected in the mean values, these values have already declined significantly by 
2017: half of the business entities still had sales of more than EUR 5.4 million in 2015; this 
threshold increased by almost EUR 1 million by the following year. However, in the last analysed 
year, the increase in the number of new producers in their initial phase, entering the market with 
lower turnover had an impact on the distribution of the indicators. Nevertheless, in the case of the 
producers achieving the highest turnover, the opposite tendency was observed, which resulted in 
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an increase in the maximum turnover of the industry in the region by more than EUR 1 billion com-
pared to 2015 (which was achieved throughout the examined period in the Czech Republic). 
However, with regard to the assets of the companies, the same trends indicated in the distri-
bution of revenues can be observed, for which the maximum values were no exception. In each of 
the three analysed years, the lowest performing 25% of the manufacturers were showing a deficit; 
the growth of revenue mostly affected the better-performing half of the population as the minimum 
detectable profit level increased by EUR 35,000 in 2016 and then decreased by EUR 140,000 in 
the case of the latter half of the sample. As indicated by the indexes of kurtosis, mean is multiple 
times higher than the median values, with the standard deviation being the highest in the top 25% 
of all companies. Larger fluctuations can be detected in the case of the financial performance indi-
cator ROE (Return on Equity), which expresses the return on equity: due to their operation resulting 
in deficit, 25% of the lowest performing manufacturers also reported negative ROE values, alt-
hough in 2015 and 2017 companies with negative equity were included in the database, therefore 
in some cases a positive return on equity of 1-2% was observed in the lower quarter.  
 
 
Table 1. Analysis of the main indicators of pharmaceutical companies operating in V4 countries in 
2014-2017. 
Financial data in million EUR 
 
Financial year (data in million euro) Net revenue Total asset Profit after tax Return on equity (ROE) (%) 
2015 
N 
Valid 262 262 262 262 
Missing 0 0 0 0 
Mean 54,3274 67,1055 3,8734 2,6873 
Std. Deviation 170,48960 318,46535 26,43710 219,74056 
Skewness 5,856 10,578 8,185 -11,855 
Std. Error of Skewness 0,150 0,150 0,150 0,150 
Minimum 0,00 0,00 -124,41 -3153,42 
Maximum 1659,75 4275,88 327,55 476,42 
Percentiles 
25 0,7600 0,9525 0,0000 1,5650 
50 5,4050 5,3900 0,2650 11,3350 
75 25,9950 30,7225 1,5525 30,2650 
2016 
N 
Valid 268 269 269 269 
Missing 1 0 0 0 
Mean 59,6463 71,3204 4,0792 -485,1092 
Std. Deviation 180,36451 356,38794 18,20703 7328,02319 
Skewness 5,287 11,168 8,097 -16,274 
Std. Error of Skewness 0,149 0,149 0,149 0,149 
Minimum 0,00 0,00 -26,09 -119906,31 
Maximum 1621,85 4950,84 215,19 167,26 
Percentiles 
25 1,0975 1,3950 0,0100 2,7650 
50 6,3250 7,3500 0,3400 9,6900 
75 26,9625 32,3800 1,6550 25,7150 
2017 
N 
Valid 285 286 285 286 
Missing 1 0 1 0 
Mean 56,5296 66,0880 2,7299 20,1765 
Std. Deviation 187,44987 281,34360 12,53011 86,18008 
Skewness 5,824 9,510 6,848 4,802 
Std. Error of Skewness 0,144 0,144 0,144 0,144 
Minimum 0,00 0,00 -42,57 -487,97 
Maximum 1757,81 3599,87 143,65 881,67 
Percentiles 
25 0,8000 0,9800 0,0000 1,3850 
50 5,1400 5,3550 0,2000 9,6550 
75 23,2850 29,9850 1,5850 26,3350 
Source: own calculation using the SPSS statistical software 
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For the lower performing half of the population, the achievable highest ROE values followed a 
clear declining tendency: there was a 2 percentage point decrease from the 11% value of 2015 
and then it stagnated at that level (see Table 1). Although the highest ROE indicator increased 
more than seven times compared to the previous year, this rise only increased the standard devia-
tion of the values of the upper quarter indicators and not their number. 
 
 
3.2 Analysis of the development of ROE indicators in countries of the region  
Amongst the Visegrád countries, Poland has by far the largest number of companies active in 
the pharmaceutical sector, which is mainly explained by the relatively large size of the national 
economy compared to other countries in Central Europe. Poland also had the highest standard 
deviation, with Polish companies having the lowest and highest ROE indicators for the analysed 
period. The minimum values indicated several thousands of negative values in 2015 and 2016, 
which were attributable to losses due to non-remunerative investments in innovation, but this val-
ue increased to -80% by the last examined year. The standard deviation of companies belonging to 
the quarter providing the weakest indicators - the majority of which are in deficit - changed signifi-
cantly in 2016, but mostly in a negative direction. Although, unprofitable Polish manufacturers 
became more profitable by 2017, the highest profit fell by nearly 1 percentage point. In 2016, the 
company providing the best return on equity had an indicator only one-third of the value of the pre-
vious year, but for the last year, with the improving profitability of manufacturers from the top quar-
ter it also multiplied. Half of the Polish pharmaceutical companies achieved and exceeded 8-10% 
return on equity each year. 
Hungary has the second highest number of pharmaceutical companies, not least due to its in-
novation policy and support for research and development. Both the distribution of quartiles and 
the development of extreme values indicate that the performance of the sector in Hungary de-
creased significantly by 2016, similarly to the other countries of the region. However, compared to 
Poland, indicators of the best performing companies in 2017 also fell by more than half, but this 
was due to declining standard deviation and lower profits of companies belonging to the top quar-
ter, rather than to a decline in overall profitability of manufacturers. While half of the business enti-
ties of the sector achieved a return on equity of at least 19% in 2015, it has fallen by 6 percentage 
points in 3 years, even though it is still the highest in the region.  
Throughout the examined period the number of pharmaceutical companies operating in the 
Czech Republic accounted for nearly half of Hungarian companies and nearly a quarter of Poland, 
despite the fact that support of innovation is the most prevalent within the economic policy of this 
country in the region. Although the same trend is observed for Czech manufacturers in terms of 
minimum values, the increase in the lowest ROE by 2017 did not even approach the rate of 
change recorded in Hungary in this field, with the indicators of the best performers falling from 
114% to 70%. While some of the companies belonging to the top quarter achieved higher profita-
bility levels in 2016, this level has remained significantly below the minimum values achieved by 
the top quarter companies of other countries within the region. Half of the pharmaceutical compa-
nies were able to generate returns of over 5-8% for their owners during the analysed period, which 
was still below the figures for all other countries within the region (it only managed to approach the 
results of the similarly weakly performing Polish manufacturers). 
Although Slovakia has the lowest number of business entities within the sector, by 2016 it has 
already risen one and a half times due to newly entering enterprises. Still, in the same year, even 
the lowest performing manufacturer managed to achieve better results than the minimum value of 
the Czech Republic indicating almost 750% of negative ROE, and the average profitability of the 
enterprises belonging to the lowest 25% exceeded that of neighbouring countries. However, this 
tendency does not apply to the entire population: while half of the business entities within the sec-
tor were able to provide at least a 22% return on equity in 2015, a decline of more than 10 per-
centage points led to a drastic decrease to 14% and 11% in the in the following years; the majority 
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of previously more profitable Slovakian companies experienced a significant decline in the last 
year (see Table 2). 
 
 
Table 2: Descriptive statistical analysis of ROE values broken down the Visegrád countries in 2015-
2017. 
 
2015 CZ PL HU SK 
Mean -2,6397 -12,3674 40,5273 16,6081 
Std. Deviation 59,90679 285,5455 56,6384 32,49464 
Minimum -293,03 -3153,42 -54,1 -73,22 
Maximum 114,6 476,42 246,93 60,11 
Percentiles 
25 0,58 0,465 6,43 2,775 
50 6,01 9,645 18,92 22,46 
75 14,52 28,99 50,97 32,7925 
     
2016 CZ PO HU SLO 
Mean -14,4454 -71,7642 -2,8425 -4972,05 
Std. Deviation 133,9327 712,4586 193,4795 24480,91 
Minimum -749,28 -7881,86 -1506,55 -119906 
Maximum 84,05 167,26 122,72 94,07 
Percentiles 
25 3,48 2,1575 3,9475 5,1725 
50 8,79 8,24 15,37 14,325 
75 20,23 23,565 30,4775 31,855 
      
2017 CZ PO HU SLO 
Mean -14,3976 31,2134 14,5063 13,5571 
Std. Deviation 99,04034 99,16099 30,10435 36,37687 
Minimum -487,97 -80,01 -104,25 -114,38 
Maximum 70,34 881,67 67,45 85,7 
Percentiles 
25 0 1,3325 2,16 5,97 
50 5,255 8,675 13,05 11,18 
75 13,74 30,775 31,62 26,625 
Source: own calculation using the SPSS statistical software 
 
 
4. RESULTS OF THE REGRESSION ANALYSIS 
According to the literature dealing with the correlation among financial performance indicators 
(Du Pont system of index numbers), development on the return on equity can be influenced by 
return on sales (ROS), the turnover rate reflecting the efficiency of asset management and the rate 
of indebtedness (external capital/equity), however, this is not proven to be significant for all fac-
tors. The explanatory power of the models established between ROE and the above independent 
variables proved to be strongest in Poland (where the value of R-square was close to 66% with the 
inclusion of only significant variables), but in the case of the Czech Republic and Hungary a strong 
correlation was observed as well (in the former case the coefficient of determination was 63.5%, in 
the latter case it was more than 57%), while the weakest but still moderately strong correlation 
was found in the case of Slovakian manufacturers (31.3%). The significance values of the F-test 
confirmed the adequacy of all the set up models. As return on equity has fluctuated significantly 
over time and did not show a clear increase or decrease in any country, financial years did not re-
main in any of the final regression models as significant factors. 
As shown by the values of the standardized coefficients, the return on equity of Czech compa-
nies was mainly influenced by the development of their profits and their debt exposure at 10% 
level of significance: with a 1 percentage point change in return on sales, the ROE would increase 
by about 4.9 percentage points and the structure of liabilities would shift towards debt. It is com-
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mon in the models set up for Czech Republic, Poland and Hungary that return on sales has a deci-
sive influence on the profit variable, i.e. the return on equity is primarily determined by the efficien-
cy of the use of resources, cost management and the success of the sales policy. The shift of liabil-
ities towards debt only approached the effect of ROS in the case of Czech companies. Although this 
effect was prevalent in Poland, the increase in leverage in both countries was accompanied by a 
noticeable decrease in ROE, meaning that primarily the loss-making companies (realizing negative 
profit) had debt exposure accompanied by higher interest expense that increases loss, while this 
was not clearly demonstrated in the case of profitable manufacturers. However, this is somewhat 
modified by the fact that on the basis of the Chi-square test performed for pharmaceutical compa-
nies categorized on the basis of their level of indebtedness and their effective operation, the null 
hypothesis concerning the independence of the former category variables cannot be rejected (see 
Table 3). 
The utilization of assets had a significant effect on the return on equity in all the countries of 
the region except the Czech Republic. Opposite to dependence on external funds, the coefficients 
of this variable have already proved positive in all cases: more efficient use of assets has been 
achieved by profitable businesses, since the value of ROE can only be increased by this efficiency 
indicator if the financial profit is positive. However, this effect was manifested to varying extent in 
each country: a one order of magnitude increase in the turnover rate increased the ROE of Polish 
pharmaceutical companies by more than 34.5 percentage points and their Hungarian competitors 
by 11.7 percentage points (see Table 4). In Hungary, the return on equity in the pharmaceutical 
industry was not significantly influenced by the level of indebtedness, but the role of the quality of 
asset management can be attributed to a much larger role. 
The latter is also confirmed by the Chi-square test of independence, which was conducted be-
tween two possible categories of the profitability of companies (profitable and unprofitable if zero-
profit companies belong to the latter) and the categories of assets based on their turnover rate 
(see Table 3). The results show a significant correlation, namely profitable pharmaceutical compa-
nies were characterized by the more effective utilization of their assets. However, it is noteworthy 
that there are differences in terms of the performance of the Visegrád countries (if it is considered 
a new category variable), namely the profitability of pharmaceutical companies is also indirectly 
influenced by their country of residence and its innovation policy. 
 
Table 3. Results of the Chi-square tests performed amongst category variables 
 
1st category variable Profit after tax (+/-) Profit after tax (+/-) Profit after tax (+/-) 
2nd category variable Total asset turnover Debt/equity ratio Country 
Pearson Chi-Square 40,523** 1,074 11,107* 
Likelihood Ratio 37,553** 1,099 12,033** 
Linear-by-Linear As-
sociation 29,131** 0,892 7,893** 
** The values shown in the table are significant at a 99% confidence level (p <0.01). 
* The values shown in the table are significant at the 95% confidence level (p <0.05). 
Source: own calculation using the SPSS statistical program 
 
 
The financial results of Slovakian pharmaceutical companies, which differed significantly from 
other countries, were influenced by the fact that the number of examined business entities within 
the sector was far below that of the neighbouring countries, and the sample population also had 
extremely low extreme values, therefore the values of coefficients can be interpreted with a fairly 
high standard error. In Slovakia, the impact of the return on sales and the amount of results were 
offset by asset efficiency and financing policies. Despite the smaller sample size, the negative co-
efficient of leverage - similarly to that of the Polish and Czech pharmaceutical companies - shows 
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that unprofitable companies tended to have higher proportions of external funding, while asset 
utilization had a decisive impact only on profitable companies. 
 
 
Table 4. Values of coefficients of significant factors affecting the development of ROE in multivari-
ate linear regression models. 
 
Country, Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
Sig. 
Correlations 
B Std. Error Beta Zero-order Partial Part 
CZ 
(Constant) 9,902 24,614  0,690    
ROS (%) 4,899 0,975 0,533 0,000 0,660 0,647 0,513 
log_debt_vs_eqiuty -28,587 6,541 -0,464 0,000 -0,610 -0,594 -0,446 
PO 
(Constant) 45,409 20,455  0,028    
ROS (%) 0,965 0,064 0,733 0,000 0,799 0,735 0,633 
log_asset_turnover_ratio 34,715 16,498 0,101 0,037 0,471 0,149 0,088 
log_debt_vs_eqiuty -14,833 5,648 -0,111 0,009 -0,229 -0,185 -0,110 
H
U 
(Constant) 0,470 2,673  0,861    
ROS (%) 2,009 0,231 0,707 0,000 0,685 0,734 0,706 
log_asset_turnover_ratio 11,720 2,933 0,324 0,000 0,275 0,444 0,324 
SK 
(Constant) 1926,382 2675,883  0,476    
log_asset_turnover_ratio 4093,852 2400,732 0,234 0,096 0,352 0,263 0,226 
log_debt_vs_eqiuty -2245,861 684,707 -0,451 0,002 -0,512 -0,465 -0,435 
Source: own calculation using the SPSS statistical software 
 
 
CONCLUSION 
The aim of the analysis was to examine the profitability situation of pharmaceutical companies 
operating in the Central and Eastern European region through the values of return on equity (ROE), 
which is, which is the most appropriate performance indicator from the aspect of equity interest 
and division of  factors breakdown. Among others, the limitations of the financial analysis included 
the fact that a different number of business entities operate in the sector in the Visegrád countries, 
and in Slovakia (which the lowest sample size) companies representing extreme figures accounted 
for a significant proportion of the total population, which sharply distorted the values of the regres-
sion coefficients. In addition, we included in the analysis the values of every company (especially 
due to the small ample size of certain countries) that had not been established in the first analysed 
year or had ceased to exist by the las year. Overall, correlation analyses confirmed that the finan-
cial risk of indebtedness and higher leverage within the industry mostly afflicts manufacturers that 
are already unprofitable, and that profitability is financed less by creditors, rather by private equity 
investors or internal funding resources. However, due to the higher fixed asset ratios of manufac-
turers, only those who could maintain a stable level of sales with well-functioning cost manage-
ment and market embeddedness were able to turn their assets into a better turnover.  All in all, 
profitability trends have improved in the last year in terms of the most important corporate indica-
tors, therefore further convergence of the innovation policy of Visegrád countries towards Western 
Europe, stopping the decline of the region in this field, and promotion of equity investors are the 
most important factors that could contribute to turning the pharmaceutical industry to a leading 
sector in Central Europe. 
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